Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Feb 19, 2019

Keywords

ClinConnect Summary

Investigators will perform a pilot study to test the translational feasibility by evaluating sensitivity and repeatability of hyperpolarized \[1-13C\]pyruvate and \[2-13C\]pyruvate in healthy human subjects (n =10 each). Each subject will be imaged twice using the same hyperpolarized substrate with an interval (\<45min) between the injections to evaluate repeatability. Finally, eight subjects will be imaged with both hyperpolarized \[1-13C\]pyruvate and \[2-13C\]pyruvate for comparison.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 through 60 years of age.
• • Healthy, with no neurological abnormalities.
• • Ability to understand and the willingness to sign a written informed consent.
• • All races and ethnicities will be included; subjects must be able to read and speak the English language.
• Exclusion Criteria:
• • Metallic foreign bodies on the scalp or cranium which may interfere with MRI acquisitions
• • Major debilitating neurological disease including, but not limited to, stroke, CVA, dementia and tumor that would limit compliance with study requirements
• • Under influence of illicit drugs which are known to alter brain physiology/metabolism including, but not limited to cocaine, lysergic acid diethylamide (LSD), and marijuana at the time of MRI/MRSI scanning.
• • Under influence of antiepileptic drugs at the time of MRI/MRSI scanning.
• • Any contraindication per MRI Screening Form including
• • Implants contraindicated at 3T, pacemakers
• • Implantable Cardioverter Defibrillator (ICD)
• • Claustrophobia
• • Medically unstable including
• • Heart failure
• • Severe left ventricular outflow tract (LVOT) obstruction
• • Unstable angina
• • Pregnancy
• • Lactating